Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer

The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer....

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 18; no. 1; pp. 89 - 18
Main Authors Xu, Shouping, Wang, Peiyuan, Zhang, Jian, Wu, Hao, Sui, Shiyao, Zhang, Jinfeng, Wang, Qin, Qiao, Kun, Yang, Weiwei, Xu, Hongbiao, Pang, Da
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 18.04.2019
BioMed Central
BMC
Subjects
RNA
Online AccessGet full text

Cover

Loading…
Abstract The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
AbstractList Abstract Background The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Methods Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. Results EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324–645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. Conclusions These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer.BACKGROUNDThe biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer.Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity.METHODSWhole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity.EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens.RESULTSEGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens.These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.CONCLUSIONSThese findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
Background The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Methods Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. Results EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. Conclusions These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy. Keywords: Ai-lncRNA, EGOT, ITPR1, Paclitaxel, Autophagy, Cancer
The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
Background The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Methods Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. Results EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324–645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. Conclusions These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited therapeutic options in the clinic. However, the potential involvement of Ai-lncRNA in paclitaxel sensitivity remains unclear in human cancer. Whole transcriptome sequencing of 33 breast specimens was performed to identify Ai-lncRNA EGOT. Next, the role of EGOT in regulation of paclitaxel sensitivity was investigated. Moreover, the mechanism of EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions was investigated in detail. Furthermore, upstream transcriptional regulation of EGOT expression was also investigated by co-immunoprecipitation and chromatin immunoprecipitation. Finally, clinical breast specimens in our cohort, TCGA and ICGC were applied to validate the role of EGOT in enhancing of paclitaxel sensitivity. EGOT enhances autophagosome accumulation via the up-regulation of ITPR1 expression, thereby sensitizing cells to paclitaxel toxicity. Mechanistically, on one hand, EGOT upregulates ITPR1 levels via formation of a pre-ITPR1/EGOT dsRNA that induces pre-ITPR1 accumulation to increase ITPR1 protein expression in cis. On the other hand, EGOT recruits hnRNPH1 to enhance the alternative splicing of pre-ITPR1 in trans via two binding motifs in EGOT segment 2 (324-645 nucleotides) in exon 1. Moreover, EGOT is transcriptionally regulated by stress conditions. Finally, EGOT expression enhances paclitaxel sensitivity via assessment of cancer specimens. These findings broaden comprehensive understanding of the biology function of Ai-lncRNAs. Proper regulation of EGOT may be a novel synergistic strategy for enhancing paclitaxel sensitivity in cancer therapy.
ArticleNumber 89
Audience Academic
Author Xu, Shouping
Zhang, Jinfeng
Wu, Hao
Pang, Da
Zhang, Jian
Yang, Weiwei
Wang, Peiyuan
Xu, Hongbiao
Sui, Shiyao
Qiao, Kun
Wang, Qin
Author_xml – sequence: 1
  givenname: Shouping
  surname: Xu
  fullname: Xu, Shouping
– sequence: 2
  givenname: Peiyuan
  surname: Wang
  fullname: Wang, Peiyuan
– sequence: 3
  givenname: Jian
  surname: Zhang
  fullname: Zhang, Jian
– sequence: 4
  givenname: Hao
  surname: Wu
  fullname: Wu, Hao
– sequence: 5
  givenname: Shiyao
  surname: Sui
  fullname: Sui, Shiyao
– sequence: 6
  givenname: Jinfeng
  surname: Zhang
  fullname: Zhang, Jinfeng
– sequence: 7
  givenname: Qin
  surname: Wang
  fullname: Wang, Qin
– sequence: 8
  givenname: Kun
  surname: Qiao
  fullname: Qiao, Kun
– sequence: 9
  givenname: Weiwei
  surname: Yang
  fullname: Yang, Weiwei
– sequence: 10
  givenname: Hongbiao
  surname: Xu
  fullname: Xu, Hongbiao
– sequence: 11
  givenname: Da
  orcidid: 0000-0003-2853-4170
  surname: Pang
  fullname: Pang, Da
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30999914$$D View this record in MEDLINE/PubMed
BookMark eNp1ks1u1DAUhSNURH_gAdggS2y6SYkdO3E2SKOqlJEqiqphbd04TsZVxg62U83M4_CkODMtdCpIFnFuzvmur3NOkyNjjUqS9zi7wJgXnzwmFc3TDFcpznCZbl8lJ5iWRUpZxY-erY-TU-_vs6jhJX2THOdZFS9MT5JfM532Rt59m6Gr69sFUmYJRmrTIRiDHZbQbZBXxuugt8qjAWSvA6xVj-Qm2GDXWuqwQQ8a0Dg41Y09BG0Nsi2aL77fYaTWsez9VKs3KPZJp15gmt16cDYobZA2QTmQk9XHF7QcV2CQjFtR7m3yuoXeq3ePz7Pkx5erxeXX9Ob2en45u0llQYqQclpWbVswUmNgvM1xRQooCCOqlpIBzqq6qXCb8Rpa3vCMFmVRUlbnrGUFAZyfJfM9t7FwLwanV-A2woIWu4J1nQAXtOyVIJwzxTijuJY0awhAAwSTtioIpVLyyPq8Zw1jvVKNVCY46A-gh1-MXorOPoiClvHPToDzR4CzP0flg1hpL1Xfg1F29IIQjCuWUZJF6ccX0ns7OhOPaqdieUlz9lfVQRxAm9bGvnKCihnjOY7B2LEu_qGKd6NWWsb0tTrWDwwfng_6Z8KnhEVBuRdIZ713qhUxMLuMRLLuBc7ElGWxz7KIWRZTlsU2OvEL5xP8_57fdWf2bQ
CitedBy_id crossref_primary_10_3389_fchem_2023_1335330
crossref_primary_10_1007_s13105_022_00924_2
crossref_primary_10_1007_s12031_021_01942_3
crossref_primary_10_1186_s13046_020_01700_0
crossref_primary_10_3390_cancers12102926
crossref_primary_10_1002_cnr2_70115
crossref_primary_10_3389_fonc_2024_1337579
crossref_primary_10_1111_and_14079
crossref_primary_10_3390_cancers16193379
crossref_primary_10_1016_j_lfs_2019_117234
crossref_primary_10_1186_s13148_023_01501_0
crossref_primary_10_1002_ctm2_241
crossref_primary_10_1016_j_prp_2021_153373
crossref_primary_10_1038_s41421_021_00342_6
crossref_primary_10_1155_2022_3922739
crossref_primary_10_1002_2211_5463_12833
crossref_primary_10_1016_j_prp_2020_153327
crossref_primary_10_1007_s11033_022_07669_7
crossref_primary_10_1007_s12094_023_03189_3
crossref_primary_10_3390_cancers12051245
crossref_primary_10_1007_s10555_020_09910_w
crossref_primary_10_3389_fphar_2021_729062
crossref_primary_10_3389_fgene_2022_919857
crossref_primary_10_1002_advs_202207257
crossref_primary_10_3389_fonc_2020_01728
crossref_primary_10_1016_j_biopha_2020_110985
crossref_primary_10_1007_s13577_021_00541_z
crossref_primary_10_1016_j_genrep_2023_101871
crossref_primary_10_1038_s41416_021_01600_w
crossref_primary_10_1093_cvr_cvaf037
crossref_primary_10_1007_s00280_023_04582_z
crossref_primary_10_1002_ctm2_1445
crossref_primary_10_1016_j_prp_2022_154274
crossref_primary_10_1186_s12943_020_1132_x
crossref_primary_10_3390_cells10102633
crossref_primary_10_3390_ijms25189922
crossref_primary_10_1038_s41417_022_00487_w
crossref_primary_10_3390_ijms21239179
crossref_primary_10_1016_j_drup_2020_100683
crossref_primary_10_1038_s41419_020_2633_7
crossref_primary_10_1128_mSystems_00245_19
crossref_primary_10_1007_s00018_022_04675_7
crossref_primary_10_1016_j_diff_2020_05_004
crossref_primary_10_3390_ijms21103711
crossref_primary_10_1186_s13045_021_01059_5
crossref_primary_10_1016_j_yexcr_2025_114434
crossref_primary_10_1186_s12929_021_00715_9
crossref_primary_10_1080_15476286_2022_2062846
crossref_primary_10_1155_2021_8493431
crossref_primary_10_18632_aging_204080
crossref_primary_10_2147_CMAR_S285254
crossref_primary_10_3389_fcell_2021_607142
crossref_primary_10_1016_j_intimp_2020_107071
crossref_primary_10_1016_j_semcancer_2021_04_017
crossref_primary_10_1111_jcmm_16545
crossref_primary_10_3390_cells11030441
crossref_primary_10_1186_s12864_020_07000_3
crossref_primary_10_3390_molecules25245986
crossref_primary_10_3389_fcell_2021_718721
crossref_primary_10_1002_btm2_10172
crossref_primary_10_1016_j_drup_2022_100851
crossref_primary_10_1016_j_dld_2022_02_011
crossref_primary_10_3389_fcell_2021_705291
crossref_primary_10_3389_fphar_2024_1387243
crossref_primary_10_1186_s12964_022_00896_2
crossref_primary_10_18632_aging_205284
crossref_primary_10_1016_j_bbagrm_2024_195017
crossref_primary_10_1186_s13046_020_01798_2
crossref_primary_10_1007_s13353_024_00848_1
crossref_primary_10_1002_jcp_30751
crossref_primary_10_1038_s41419_019_1835_3
crossref_primary_10_1186_s13058_023_01672_x
crossref_primary_10_4049_jimmunol_1900776
crossref_primary_10_1038_s41598_021_86097_2
crossref_primary_10_1186_s12943_020_01181_x
crossref_primary_10_3389_fnins_2021_682247
crossref_primary_10_3389_fcell_2022_869011
crossref_primary_10_3389_fcell_2022_808591
crossref_primary_10_1016_j_prp_2024_155101
crossref_primary_10_3390_ijms24065086
crossref_primary_10_1152_ajpcell_00790_2024
crossref_primary_10_1186_s13046_019_1421_7
crossref_primary_10_3390_cancers14092101
crossref_primary_10_1016_j_gendis_2023_04_015
crossref_primary_10_2147_OTT_S274623
crossref_primary_10_1016_j_canlet_2022_215929
crossref_primary_10_1080_14737159_2023_2169072
crossref_primary_10_1007_s10495_022_01750_z
crossref_primary_10_1007_s10549_020_05940_8
crossref_primary_10_1177_1559325819899265
Cites_doi 10.1016/j.celrep.2012.02.001
10.1080/15548627.2017.1312041
10.1158/1078-0432.CCR-17-0419
10.1038/ng.1049
10.1016/j.cmet.2016.11.016
10.1080/15548627.2015.1106663
10.1016/j.ccell.2014.09.015
10.1038/ng1901
10.1016/j.bbrc.2015.02.037
10.1038/nature23451
10.1186/s12943-017-0696-6
10.1101/gad.287524.116
10.1016/j.ccell.2015.05.009
10.1155/2015/473942
10.1042/bj3450357
10.1038/ncomms15916
10.1038/ncb3231
10.1016/j.jmb.2013.01.022
10.1038/nrc3081
10.1038/ncomms15760
10.1038/ncb980
10.1016/j.ccell.2016.09.010
10.1038/ncb3328
10.1038/cddis.2017.205
10.1038/ncb3338
10.1038/ncomms7779
10.1016/j.cell.2014.03.008
10.1016/j.mam.2016.01.003
10.1038/onc.2015.340
10.1038/ncomms13608
10.1016/j.pharmthera.2016.04.009
10.1038/nsmb.2219
10.1161/CIRCRESAHA.114.305197
10.1073/pnas.1507882112
10.1016/j.cell.2013.02.012
10.1007/s13277-015-3746-y
10.1038/onc.2012.92
10.1038/nrc.2016.116
10.1172/JCI28833
10.1038/nmeth.1528
10.1038/ncb3473
10.1038/s41467-017-01969-4
10.1038/nsmb.2480
10.1016/j.cell.2011.10.026
10.1016/j.tcb.2017.06.003
10.1007/s13238-014-0053-0
10.1073/pnas.0700007104
10.4161/auto.7.10.16610
10.1016/j.ccell.2015.02.006
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s). 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s). 2019
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-019-1017-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 18
ExternalDocumentID oai_doaj_org_article_2885e58541bc40d2aada212f96244cc8
PMC6471868
A583187420
30999914
10_1186_s12943_019_1017_z
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
China
GeographicLocations_xml – name: China
– name: United States--US
GrantInformation_xml – fundername: ;
  grantid: 201402003
– fundername: ;
  grantid: Nn102017-02
– fundername: ;
  grantid: 81602323, 81872149
– fundername: ;
  grantid: JCQN2018-03
– fundername: ;
  grantid: JY2016-02
– fundername: ;
  grantid: 2014BAI09B08
– fundername: ;
  grantid: WLD-QN1706
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c626t-8479ff652b1a58f31926a6252ebcc5a109bd91f08baf8d804676745b35f562a13
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 00:53:25 EDT 2025
Thu Aug 21 18:27:12 EDT 2025
Tue Aug 05 09:54:24 EDT 2025
Fri Jul 25 19:54:49 EDT 2025
Tue Jun 17 21:37:36 EDT 2025
Tue Jun 10 20:47:28 EDT 2025
Thu Apr 03 06:56:09 EDT 2025
Thu Apr 24 23:09:49 EDT 2025
Tue Jul 01 01:01:16 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords ITPR1
Ai-lncRNA
Autophagy
EGOT
Paclitaxel
Cancer
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c626t-8479ff652b1a58f31926a6252ebcc5a109bd91f08baf8d804676745b35f562a13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2853-4170
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-019-1017-z
PMID 30999914
PQID 2211537435
PQPubID 42702
PageCount 18
ParticipantIDs doaj_primary_oai_doaj_org_article_2885e58541bc40d2aada212f96244cc8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6471868
proquest_miscellaneous_2211950420
proquest_journals_2211537435
gale_infotracmisc_A583187420
gale_infotracacademiconefile_A583187420
pubmed_primary_30999914
crossref_citationtrail_10_1186_s12943_019_1017_z
crossref_primary_10_1186_s12943_019_1017_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-04-18
PublicationDateYYYYMMDD 2019-04-18
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-18
  day: 18
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References TP Xu (1017_CR21) 2017; 8
X Xue (1017_CR22) 2016; 35
TR Cech (1017_CR7) 2014; 157
CE Adkins (1017_CR13) 2000; 345
S Vijayaraghavan (1017_CR32) 2017; 8
L Shan (1017_CR18) 2016; 30
I Sergin (1017_CR31) 2014; 115
S Xu (1017_CR23) 2017; 16
JJ Tyson (1017_CR34) 2011; 11
CA Lyssiotis (1017_CR45) 2017; 27
S Huang (1017_CR25) 2015; 11
YJ Jeon (1017_CR4) 2015; 27
RK Amaravadi (1017_CR30) 2007; 117
J Zhang (1017_CR10) 2017; 13
Y Yu (1017_CR1) 2015; 28
NY Fu (1017_CR16) 2007; 104
A Salameh (1017_CR24) 2015; 112
JS Carroll (1017_CR47) 2017; 17
PJ Batista (1017_CR8) 2013; 152
X Liu (1017_CR40) 2016; 18
LW Dong (1017_CR39) 2011; 7
J Joung (1017_CR9) 2017; 548
F Natale (1017_CR20) 2017; 8
JS Carroll (1017_CR35) 2006; 38
L Wang (1017_CR38) 2015; 458
K Wang (1017_CR19) 2015; 6
SC Huelga (1017_CR43) 2012; 1
N Mizushima (1017_CR3) 2011; 147
SP Xu (1017_CR14) 2015; 36
L Amicone (1017_CR26) 2015; 2015
I Akerman (1017_CR17) 2017; 25
H Choudhry (1017_CR46) 2016; 47-48
Q Zeng (1017_CR37) 2018; 24
TR Mercer (1017_CR27) 2013; 20
Y Luo (1017_CR2) 2014; 5
Y Katz (1017_CR42) 2010; 7
M Chen (1017_CR29) 2012; 19
B Bilanges (1017_CR33) 2017; 8
A Bhan (1017_CR48) 2013; 425
DP Hall (1017_CR15) 2014; 26
X Li (1017_CR28) 2016; 18
M Ghoussaini (1017_CR49) 2012; 44
R Amaravadi (1017_CR36) 2016; 30
E Domenech (1017_CR5) 2015; 17
A Lin (1017_CR11) 2017; 19
RA Veldhoen (1017_CR6) 2013; 32
W Echevarria (1017_CR12) 2003; 5
C Wigerup (1017_CR44) 2016; 164
P Zhu (1017_CR41) 2016; 7
References_xml – volume: 1
  start-page: 167
  year: 2012
  ident: 1017_CR43
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2012.02.001
– volume: 13
  start-page: 1004
  year: 2017
  ident: 1017_CR10
  publication-title: Autophagy
  doi: 10.1080/15548627.2017.1312041
– volume: 24
  start-page: 445
  year: 2018
  ident: 1017_CR37
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-17-0419
– volume: 44
  start-page: 312
  year: 2012
  ident: 1017_CR49
  publication-title: Nat Genet
  doi: 10.1038/ng.1049
– volume: 25
  start-page: 400
  year: 2017
  ident: 1017_CR17
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2016.11.016
– volume: 11
  start-page: 2172
  year: 2015
  ident: 1017_CR25
  publication-title: Autophagy
  doi: 10.1080/15548627.2015.1106663
– volume: 26
  start-page: 738
  year: 2014
  ident: 1017_CR15
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2014.09.015
– volume: 38
  start-page: 1289
  year: 2006
  ident: 1017_CR35
  publication-title: Nat Genet
  doi: 10.1038/ng1901
– volume: 458
  start-page: 816
  year: 2015
  ident: 1017_CR38
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.02.037
– volume: 548
  start-page: 343
  year: 2017
  ident: 1017_CR9
  publication-title: Nature
  doi: 10.1038/nature23451
– volume: 16
  start-page: 129
  year: 2017
  ident: 1017_CR23
  publication-title: Mol Cancer
  doi: 10.1186/s12943-017-0696-6
– volume: 30
  start-page: 1913
  year: 2016
  ident: 1017_CR36
  publication-title: Genes Dev
  doi: 10.1101/gad.287524.116
– volume: 28
  start-page: 82
  year: 2015
  ident: 1017_CR1
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.05.009
– volume: 2015
  start-page: 473942
  year: 2015
  ident: 1017_CR26
  publication-title: Biomed Res Int
  doi: 10.1155/2015/473942
– volume: 345
  start-page: 357
  issue: Pt 2
  year: 2000
  ident: 1017_CR13
  publication-title: Biochem J
  doi: 10.1042/bj3450357
– volume: 8
  year: 2017
  ident: 1017_CR32
  publication-title: Nat Commun
  doi: 10.1038/ncomms15916
– volume: 17
  start-page: 1304
  year: 2015
  ident: 1017_CR5
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3231
– volume: 425
  start-page: 3707
  year: 2013
  ident: 1017_CR48
  publication-title: J Mol Biol
  doi: 10.1016/j.jmb.2013.01.022
– volume: 11
  start-page: 523
  year: 2011
  ident: 1017_CR34
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3081
– volume: 8
  year: 2017
  ident: 1017_CR20
  publication-title: Nat Commun
  doi: 10.1038/ncomms15760
– volume: 5
  start-page: 440
  year: 2003
  ident: 1017_CR12
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb980
– volume: 30
  start-page: 708
  year: 2016
  ident: 1017_CR18
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.010
– volume: 18
  start-page: 431
  issue: 4
  year: 2016
  ident: 1017_CR40
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3328
– volume: 8
  year: 2017
  ident: 1017_CR21
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2017.205
– volume: 18
  start-page: 561
  year: 2016
  ident: 1017_CR28
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3338
– volume: 6
  start-page: 6779
  year: 2015
  ident: 1017_CR19
  publication-title: Nat Commun
  doi: 10.1038/ncomms7779
– volume: 157
  start-page: 77
  year: 2014
  ident: 1017_CR7
  publication-title: Cell
  doi: 10.1016/j.cell.2014.03.008
– volume: 47-48
  start-page: 35
  year: 2016
  ident: 1017_CR46
  publication-title: Mol Asp Med
  doi: 10.1016/j.mam.2016.01.003
– volume: 35
  start-page: 2746
  year: 2016
  ident: 1017_CR22
  publication-title: Oncogene
  doi: 10.1038/onc.2015.340
– volume: 7
  year: 2016
  ident: 1017_CR41
  publication-title: Nat Commun
  doi: 10.1038/ncomms13608
– volume: 164
  start-page: 152
  year: 2016
  ident: 1017_CR44
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2016.04.009
– volume: 19
  start-page: 346
  year: 2012
  ident: 1017_CR29
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.2219
– volume: 115
  start-page: 817
  year: 2014
  ident: 1017_CR31
  publication-title: Circ Res
  doi: 10.1161/CIRCRESAHA.114.305197
– volume: 112
  start-page: 8403
  year: 2015
  ident: 1017_CR24
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1507882112
– volume: 152
  start-page: 1298
  year: 2013
  ident: 1017_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2013.02.012
– volume: 36
  start-page: 9807
  year: 2015
  ident: 1017_CR14
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3746-y
– volume: 32
  start-page: 736
  year: 2013
  ident: 1017_CR6
  publication-title: Oncogene
  doi: 10.1038/onc.2012.92
– volume: 17
  start-page: 54
  year: 2017
  ident: 1017_CR47
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.116
– volume: 117
  start-page: 326
  year: 2007
  ident: 1017_CR30
  publication-title: J Clin Invest
  doi: 10.1172/JCI28833
– volume: 7
  start-page: 1009
  year: 2010
  ident: 1017_CR42
  publication-title: Nat Methods
  doi: 10.1038/nmeth.1528
– volume: 19
  start-page: 238
  year: 2017
  ident: 1017_CR11
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3473
– volume: 8
  start-page: 1804
  year: 2017
  ident: 1017_CR33
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-01969-4
– volume: 20
  start-page: 300
  year: 2013
  ident: 1017_CR27
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.2480
– volume: 147
  start-page: 728
  year: 2011
  ident: 1017_CR3
  publication-title: Cell
  doi: 10.1016/j.cell.2011.10.026
– volume: 27
  start-page: 863
  year: 2017
  ident: 1017_CR45
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2017.06.003
– volume: 5
  start-page: 469
  year: 2014
  ident: 1017_CR2
  publication-title: Protein Cell
  doi: 10.1007/s13238-014-0053-0
– volume: 104
  start-page: 10051
  year: 2007
  ident: 1017_CR16
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0700007104
– volume: 7
  start-page: 1222
  year: 2011
  ident: 1017_CR39
  publication-title: Autophagy
  doi: 10.4161/auto.7.10.16610
– volume: 27
  start-page: 354
  year: 2015
  ident: 1017_CR4
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.02.006
SSID ssj0017874
Score 2.5523453
Snippet The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance have limited...
Background The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel resistance...
Abstract Background The biology function of antisense intronic long noncoding RNA (Ai-lncRNA) is still unknown. Meanwhile, cancer patients with paclitaxel...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 89
SubjectTerms Adult
Aged
Ai-lncRNA
Alternative splicing
Animals
Antineoplastic agents
Antineoplastic Agents, Phytogenic - pharmacology
Antisense RNA
Autophagosomes - metabolism
Autophagy
Autophagy - drug effects
Autophagy - genetics
Binding sites
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Cancer
Cancer patients
Cancer therapies
Cell Line, Tumor
Chemotherapy
Chromatin
Cytotoxicity
Double-stranded RNA
Drug Resistance, Neoplasm - genetics
EGOT
Experiments
Female
Gene expression
Gene Expression Regulation, Neoplastic
Gene regulation
Genomes
Health aspects
Heterogeneous-Nuclear Ribonucleoprotein Group F-H - genetics
Heterogeneous-Nuclear Ribonucleoprotein Group F-H - metabolism
Humans
Hypoxia
Immunoprecipitation
Inositol 1,4,5-Trisphosphate Receptors - antagonists & inhibitors
Inositol 1,4,5-Trisphosphate Receptors - genetics
Inositol 1,4,5-Trisphosphate Receptors - metabolism
ITPR1
Medical prognosis
Metabolism
Mice
Mice, Nude
Middle Aged
Novels
Nucleotides
Paclitaxel
Paclitaxel - pharmacology
Phagocytosis
Protein Binding
Protein interaction
Ribonucleic acid
RNA
RNA, Double-Stranded - genetics
RNA, Double-Stranded - metabolism
RNA, Long Noncoding - genetics
RNA, Long Noncoding - metabolism
RNA, Small Interfering - genetics
RNA, Small Interfering - metabolism
RNA-protein interactions
Signal Transduction
Survival Analysis
Toxicity
Transcription
Transcription (Genetics)
Transcriptome
Tumors
Up-regulation
Xenograft Model Antitumor Assays
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fi9QwEA5yoPgiev6qnhJBEIRwbdqk6eMqd57CnXLswb2FJE3uFpbssduV3f1z_EudabvLFkFffGubpGk6XzIzZPINIe9D6UywoWR18AUrTC5YJWrL8jwYWUtuncCDwucX8uyq-HYtrvdSfWFMWEcP3P24Y66U8GDTFpl1RVpzY2oDy22oJCgm59pjvqDzts5Uv38AMCz6PcxMyeMFaLUC44YqhhBkm4EWasn6_1yS93TSMF5yTwGdPiaPesuRjrovfkLu-XhI7ne5JNeH5MF5v0v-lPwaTdg0usuLET358n1MfbxFVo14Q80SeQTMzZouMHC9mWz8goLXjEzdKz-lbt3MmtkK3tOs6c-Jocu7eZesHsRHZ4F-Hf-4zKhf9eGzkdo1hX4Y9mVi3V631A-TSJGJYt6dm1jADW3TAVKHMJs_I1enJ-PPZ6zPxcAcuDwNAyVWhSAFt5kRKsDE5dKA78S9dU6YLK1sXWUhVdYEVSvwupElSNhcBLCwTJY_JwdxFv1LQkuwIksPZkElXRF4BQ3yOsiQCq7qvOAJSbey0a4nKsd8GVPdOixK6k6cGsSJEWql3iTk467JXcfS8bfKn1Dgu4pIsN0-ANjpHnb6X7BLyAeEi8ZlAD7Omf40AwwRCbX0SKgc0x3yNCFHg5owfd2weAs43S8fC83BLRc5GHciIe92xdgSQ-Kiny27OpVI21e86PC5G1KOdn-VFQkpB8gdjHlYEie3Lbm4RGtFqlf_4ye9Jg85zjmkxlRH5KCZL_0bsOEa-7adrr8BcAxEBA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA66ovgiut6qq0QQBCFsmzZp-iSj7LoKu8oyC_NW0jSZHRjacdqRmfk5_lLPaTPjFmHf2iZpGs69OfkOIe9darQrXMpKZxOW6FiwTJQFi2OnZSl5YQQeFD6_kGdXyfeJmPgfbo1Pq9zpxE5Rl7XBf-THHCIVEYO9E58WvxhWjcLdVV9C4y65h9BlyNXpZB9wRcCMid_JjJQ8bsC2JZg9lDFkRLYd2KIOsv9_xXzDMg2zJm-YodPH5JH3H-moJ_gTcsdWh-R-X1Fyc0genPu98qfkz2jG5pW5vBjRk68_xtRW14itUU2pXiGagJ5uaIPp6-1saxsKsTPida_tnJpNW7f1Gt7TbujvmaarxbIvWQ9EpLWj38Y_LyNq1z6JtqLFhsI8DOfSVdlddwAQs4oiHsWyPz3RwA3tigJSg8y2fEauTk_GX86Yr8jADAQ-LQNTljknBS8iLZQD8eVSQwTFbWGM0FGYFWUWuVAV2qlSQeyNWEGiiIUDP0tH8XNyUNWVfUloCr5kasE5yKRJHM9gQFw66ULBVRknPCDhjja58XDlWDVjnndhi5J5T84cyIl5amm-DcjH_ZBFj9VxW-fPSPB9R4TZ7h7Uy2nupTbnSgkLAVUSFSYJS651qcHWu0yCV2SMCsgHZJcclQF8nNH-TAMsEWG18pFQMRY95GFAjgY9QYjNsHnHcLlXIk3-j-UD8m7fjCMxMa6y9arvk4mwe8WLnj_3S4rR-8-iJCDpgHMHax62VLPrDmJcos8i1avbP-s1echRmhD6Uh2Rg3a5sm_AR2uLt50g_gVOBTvM
  priority: 102
  providerName: ProQuest
Title Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/30999914
https://www.proquest.com/docview/2211537435
https://www.proquest.com/docview/2211950420
https://pubmed.ncbi.nlm.nih.gov/PMC6471868
https://doaj.org/article/2885e58541bc40d2aada212f96244cc8
Volume 18
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELb2Q0x7QTBgBEZlJCQkpEDixInzgFCHOgZSy1S10t4ix7G7SlUy0hQ1_XP4S7lL0rKIiQfe2tqX1L273nfx-TtC3phQSZOY0E6N9m1fetyOeJrYnmdkkAYsURwPCg9HweXU_3bNr_fItr1V-wMu703tsJ_UtFi8X_-oPoHDf6wdXgQflhCzfKwKimw0MHuzTw4hMIXY0GDo_9lUANv0243Ne8WOyZGHgCly_U6Uqsn8__7LvhOzuvWUdwLUxSPysEWWtN-YwmOyp7MT8qDpNVmdkKNhu4v-hPzqz-1FpsajPh18-T6hOrtB1o1sRuUKeQbkrKJLLGwv5xu9pJBVI5P3Wi-oqsq8zNdwnbKiP-eSrm6Lppk9qJfmhn6dXI1dqtdteW1Gk4rCfWy8l8zS-nVNDTHPKDJVFM25iiW8oXW7QKrQDIunZHoxmHy-tNteDbaClKi0IchFxgScJa7kwoBjs0BCbsV0ohSXrhMlaeQaRyTSiFRAVo4sQjzxuAEEJl3vGTnI8kw_JzQElBlqgA1RoHzDIhDwUhMYhzORej6ziLPVTaxaInPsp7GI64RGBHGj2Rg0ixVsYbyxyLudyG3D4vGvyeeo8N1EJOCuP8iLWdz6c8yE4BpSLd9NlO-kTMpUAgowUQB4SSlhkbdoLjEaLnw5JdvTDrBEJNyK-1x42A6RORY568wE91bd4a3BxVvviBmk7dwD8Mct8no3jJJYMpfpfNXMibhTX-K0sc_dkrZmbpGwY7mdNXdHsvlNTT4eIJoJxIv_lnxJjhn6HPJlijNyUBYr_QqAXZn0yH54HfbI4flgdDXu1Y9HerUL_wY5Zk_z
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1tb9MwELbGEC9fEIy3wAAjgZCQoiVOnDgfECqw0bK1oKmT-i04jt1VqpLSptD05_AD-I3cJWlZhLRv-9bWL4l157t76vNzhLwyoZImMaGdGu3bvvS4HfE0sT3PyCANWKI4XhTuD4Lumf9lxEc75M_mLgymVW5sYmWo01zhf-QHDJAK98Df8fezHzZWjcLT1U0JjVotjnX5CyDb4l3vE8j3NWNHh8OPXbupKmArCN4LG8xxZEzAWeJKLgyoIAskoACmE6W4dJ0oSSPXOCKRRqQC8CPy3fDE4wZiBel6MO81ch0cr4NgLxxtAZ4Lyu83J6euCA4W4Et9zFaKbFR8e93yfVWJgP8dwQVP2M7SvOD2ju6SO028Sju1gt0jOzrbIzfqCpblHrnZb87m75PfnYk9zdTpoEMPP38dUp2dI5dHNqZyiewFclzSBabLF5O1XlDA6sgPvtJTqsoiL_IVzFOU9OdE0uVsrsdNXTGaG9obfjt1qV41SbsZTUoKz7HxWTJLq88V4cQko8h_Ma9vayzgC62KEFKFyj1_QM6uRFYPyW6WZ_oxoSHErqGGYCQKlG9YBAO81ATG4Uykns8s4mxkE6uGHh2rdEzjCiaJIK7FGYM4MS8ujNcWebsdMqu5QS7r_AEFvu2ItN7VD_l8HDdWImZCcA0AzncT5TspkzKVEFuYKIAoTClhkTeoLjEaH3g5JZs7FLBEpPGKO1x4WGSRORbZb_UEo6HazRuFixujtYj_bTGLvNw240hMxMt0vqz7RNyppnhU6-d2SR6ijcj1LRK2NLe15nZLNjmvKM0DjJEC8eTy13pBbnWH_ZP4pDc4fkpuM9xZSLsp9sluMV_qZxAfFsnzalNS8v2qrcBf_F53Yw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ai-lncRNA+EGOT+enhancing+autophagy+sensitizes+paclitaxel+cytotoxicity+via+upregulation+of+ITPR1+expression+by+RNA-RNA+and+RNA-protein+interactions+in+human+cancer&rft.jtitle=Molecular+cancer&rft.au=Xu%2C+Shouping&rft.au=Wang%2C+Peiyuan&rft.au=Zhang%2C+Jian&rft.au=Wu%2C+Hao&rft.date=2019-04-18&rft.pub=BioMed+Central&rft.eissn=1476-4598&rft.volume=18&rft_id=info:doi/10.1186%2Fs12943-019-1017-z&rft_id=info%3Apmid%2F30999914&rft.externalDocID=PMC6471868
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon